| Drug General Information |
| Drug ID |
D04SQJ
|
| Former ID |
DIB012916
|
| Drug Name |
EW-A-401
|
| Indication |
Peripheral vascular disease [ICD9: 443.9; ICD10:I73.9]
|
Phase 1 |
[1]
|
|---|
| Company |
Sangamo BioSciences
|
| Target and Pathway |
| Target(s) |
Vascular endothelial growth factor receptor 1 |
Target Info |
Modulator |
|
|---|
|
KEGG Pathway
|
Ras signaling pathway
|
|
Rap1 signaling pathway
|
|
Cytokine-cytokine receptor interaction
|
|
HIF-1 signaling pathway
|
|
Endocytosis
|
|
PI3K-Akt signaling pathway
|
|
Focal adhesion
|
|
Transcriptional misregulation in cancer
|
|
Rheumatoid arthritis
|
|
Pathway Interaction Database
|
Glypican 1 network
|
|
HIF-2-alpha transcription factor network
|
|
S1P3 pathway
|
|
VEGF and VEGFR signaling network
|
|
VEGFR1 specific signals
|
|
Signaling events mediated by VEGFR1 and VEGFR2
|
|
Reactome
|
Neurophilin interactions with VEGF and VEGFR
|
|
VEGF binds to VEGFR leading to receptor dimerization
|
|
WikiPathways
|
Focal Adhesion
|
|
Signaling by VEGF
|
|
Angiogenesis
|
| References |
| REF 1 | ClinicalTrials.gov (NCT00080392) EW-A-401 to Treat Intermittent Claudication. U.S. National Institutes of Health. |
|---|
